The estimated Net Worth of Group L Pcolumn Group Iii, ... is at least $2.71 Million dollars as of 27 August 2020. Group Iii owns over 62,494 units of Ngm Biopharmaceuticals Inc stock worth over $2,714,921 and over the last 4 years Group sold NGM stock worth over $0.
Group has made over 6 trades of the Ngm Biopharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Group bought 62,494 units of NGM stock worth $1,114,268 on 27 August 2020.
The largest trade Group's ever made was buying 72,583 units of Ngm Biopharmaceuticals Inc stock on 24 July 2020 worth over $1,301,413. On average, Group trades about 37,112 units every 6 days since 2020. As of 27 August 2020 Group still owns at least 1,762,936 units of Ngm Biopharmaceuticals Inc stock.
You can see the complete history of Group Iii stock trades at the bottom of the page.
Over the last 5 years, insiders at Ngm Biopharmaceuticals Inc have traded over $9,159,599 worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth $177,396,366 . The most active insiders traders include Peter Svennilson, David V Goeddel, and Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $171,092. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth $15,615.
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include: